1
|
Fukuda Y, Morioka H, Yamamoto S, Iguchi M, Umeda S, Asahara T, Kanda K, Oka K, Nakayama G, Yagi T. Catheter-related bloodstream infection caused by Lacticaseibacillus paracasei: A case report and literature review. J Infect Chemother 2024:S1341-321X(24)00002-3. [PMID: 38184108 DOI: 10.1016/j.jiac.2023.12.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Revised: 12/14/2023] [Accepted: 12/31/2023] [Indexed: 01/08/2024]
Abstract
Catheter-related bloodstream infections (CRBSIs) caused by Lactobacillus spp. and Lacticaseibacillus spp. are rare, and their clinical course and optimal treatment remain uncertain. In this report, we present a 46-year-old male patient who experienced clinically diagnosed Lacticaseibacillus paracasei CRBSI on four separate occasions, despite receiving systemic administration of antibiotics and antimicrobial lock therapy. The patient did not develop L. paracasei bacteremia after catheter removal. This case report furthers our knowledge of CRBSI caused by Lactobacillus and related genera and highlights the need for further research.
Collapse
Affiliation(s)
- Yuto Fukuda
- Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan; Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Hiroshi Morioka
- Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| | - Shuta Yamamoto
- Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo, 186-8650, Japan
| | - Mitsutaka Iguchi
- Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Shinichi Umeda
- Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Takashi Asahara
- Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo, 186-8650, Japan
| | - Kohei Kanda
- Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Keisuke Oka
- Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Goro Nakayama
- Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Tetsuya Yagi
- Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| |
Collapse
|
2
|
Suzuki T, Iwamoto N, Tsuzuki S, Kakumoto Y, Suzuki M, Ashida S, Oshiro Y, Nemoto T, Kanda K, Okuhama A, Yamada G, Inada M, Sato L, Miyazato Y, Akiyama Y, Saito S, Morioka S, Ujiie M, Hayakawa K, Sugiyama M, Mizokami M, Kodama EN, Ohmagari N. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement. Eur J Clin Invest 2022; 52:e13808. [PMID: 35506823 PMCID: PMC9541409 DOI: 10.1111/eci.13808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 05/02/2022] [Accepted: 05/03/2022] [Indexed: 01/08/2023]
Affiliation(s)
- Tetsuya Suzuki
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
- Emerging and Re‐emerging Infectious Diseases, Graduate School of MedicineTohoku UniversitySendaiJapan
| | - Noriko Iwamoto
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
- Emerging and Re‐emerging Infectious Diseases, Graduate School of MedicineTohoku UniversitySendaiJapan
| | - Shinya Tsuzuki
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
- Faculty of Medicine and Health SciencesUniversity of AntwerpAntwerpBelgium
| | - Yuko Kakumoto
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Michiyo Suzuki
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Shinobu Ashida
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Yusuke Oshiro
- Clinical Laboratory DepartmentNational Center for Global Health and MedicineTokyoJapan
| | - Takeshi Nemoto
- Clinical Laboratory DepartmentNational Center for Global Health and MedicineTokyoJapan
| | - Kohei Kanda
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Ayako Okuhama
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Gen Yamada
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Makoto Inada
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Lubna Sato
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Yusuke Miyazato
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Yutaro Akiyama
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Sho Saito
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
- Emerging and Re‐emerging Infectious Diseases, Graduate School of MedicineTohoku UniversitySendaiJapan
| | - Shinichiro Morioka
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
- Emerging and Re‐emerging Infectious Diseases, Graduate School of MedicineTohoku UniversitySendaiJapan
| | - Mugen Ujiie
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Kayoko Hayakawa
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
| | - Masaya Sugiyama
- Genome Medical Sciences Project, Research InstituteNational Center for Global Health and MedicineIchikawaJapan
- Department of Viral Pathogenesis and ControlsNational Center for Global Health and MedicineIchikawaJapan
| | - Masashi Mizokami
- Genome Medical Sciences Project, Research InstituteNational Center for Global Health and MedicineIchikawaJapan
| | - Eiichi N. Kodama
- Department of Infectious Disease, International Research Institute of Disaster ScienceTohoku UniversitySendaiJapan
| | - Norio Ohmagari
- Disease Control and Prevention CenterNational Center for Global Health and MedicineTokyoJapan
- Emerging and Re‐emerging Infectious Diseases, Graduate School of MedicineTohoku UniversitySendaiJapan
| |
Collapse
|
3
|
Maruki T, Iwamoto N, Kanda K, Okumura N, Yamada G, Ishikane M, Ujiie M, Saito M, Fujimoto T, Kageyama T, Saito T, Saito S, Suzuki T, Ohmagari N. Two cases of breakthrough SARS-CoV-2 infections caused by the Omicron variant (B.1.1.529 lineage) in international travelers to Japan. Clin Infect Dis 2022; 75:e354-e356. [PMID: 34979547 PMCID: PMC8755371 DOI: 10.1093/cid/ciab1072] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Indexed: 12/02/2022] Open
Abstract
In November 2021, the World Health Organization designated a new SARS-CoV-2 variant of concern, Omicron (PANGO lineage B.1.1.529). We report on first two cases of breakthrough COVID-19 caused by Omicron in Japan among international travelers returning from the country with undetected infection. The spread of infection by Omicron were considered.
Collapse
Affiliation(s)
- Taketomo Maruki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Noriko Iwamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Nobumasa Okumura
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Gen Yamada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mugen Ujiie
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | | | | | | | - Tomoya Saito
- National Institute of Infectious Diseases, Tokyo, Japan
| | - Shinji Saito
- National Institute of Infectious Diseases, Tokyo, Japan
| | - Tadaki Suzuki
- National Institute of Infectious Diseases, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
4
|
Ide S, Saito S, Akazawa T, Furuya T, Masuda J, Nagashima M, Asai Y, Ogawa T, Yamamoto R, Ishioka H, Kanda K, Okuhama A, Wakimoto Y, Suzuki T, Akiyama Y, Miyazato Y, Nakamura K, Nakamoto T, Nomoto H, Moriyama Y, Ota M, Morioka S, Matsuda W, Uemura T, Kobayashi K, Sasaki R, Katagiri D, Kutsuna S, Hayakawa K, Ohmagari N. Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019. IDCases 2021; 26:e01343. [PMID: 34804800 PMCID: PMC8596653 DOI: 10.1016/j.idcr.2021.e01343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 11/14/2021] [Accepted: 11/16/2021] [Indexed: 11/28/2022] Open
Abstract
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13–21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5–0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C4) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C18) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary. A COVID-19 patient undergoing ECMO was administered remdesivir. The loading dosage was 200 mg at 7:00 PM on day 12. From days 13–21, it was 100 mg daily at 0:00 PM administered within 1 h. The half-lives of remdesivir and GS-441524 were 3.2 and 35.1 h, respectively. Plasma concentrations of remdesivir and GS-441524 must be monitored during ECMO.
Collapse
Affiliation(s)
- Satoshi Ide
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | - Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | - Tsubasa Akazawa
- Pharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takahito Furuya
- Pharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan
| | - Junichi Masuda
- Pharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan
| | - Maki Nagashima
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yusuke Asai
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tatsunori Ogawa
- Medical Equipment Management Office, National Center for Global Health and Medicine, Tokyo, Japan
| | - Ryohei Yamamoto
- Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Haruhiko Ishioka
- Department of Anesthesiology and Critical Care Medicine, Jichi Medical University Saitama Medical Center, Saitama, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Ayako Okuhama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuji Wakimoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tetsuya Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | - Yutaro Akiyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yusuke Miyazato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Keiji Nakamura
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takato Nakamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hidetoshi Nomoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | - Yuki Moriyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | - Masayuki Ota
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinichiro Morioka
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | - Wataru Matsuda
- Department of Emergency Medicine and Critical Care, Trauma Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tatsuki Uemura
- Department of Emergency Medicine and Critical Care, Trauma Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kentaro Kobayashi
- Department of Emergency Medicine and Critical Care, Trauma Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Ryo Sasaki
- Department of Emergency Medicine and Critical Care, Trauma Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Daisuke Katagiri
- Department of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Kutsuna
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kayoko Hayakawa
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan
| |
Collapse
|
5
|
Okuhama A, Hotta M, Ishikane M, Kawashima A, Miyazato Y, Terada M, Yamada G, Kanda K, Inada M, Sato L, Sato M, Akiyama Y, Suzuki T, Nakamoto T, Nomoto H, Ide S, Nakamura K, Saito S, Kinoshita N, Yamamoto K, Morioka S, Ujiie M, Hayakawa K, Kustuna S, Shida Y, Tajima T, Teruya K, Funato Y, Yamamoto M, Izumi S, Hojo M, Sugiyama H, Ohmagari N. Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease. J Infect Chemother 2021; 28:217-223. [PMID: 34756574 PMCID: PMC8526433 DOI: 10.1016/j.jiac.2021.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 10/08/2021] [Accepted: 10/17/2021] [Indexed: 01/08/2023]
Abstract
OBJECTIVES To alleviate the overflow of coronavirus disease 2019 (COVID-19) patients in hospitals, less invasive and simple criteria are required to triage the patients. We evaluated the relationship between COVID-19 severity and fatty liver on plain computed tomography (CT) scan performed on admission. METHODS In this retrospective cohort study, we considered all COVID-19 patients at a large tertiary care hospital between January 31 and August 31, 2020. COVID-19 severity was categorized into severe (moderate and severe) and non-severe (asymptomatic and mild) groups, based on the Japanese National COVID-19 guidelines. Fatty liver was detected on plain CT scan. Multivariate logistic regression analysis was performed to evaluate factors associated with severe COVID-19. RESULTS Of 222 patients (median age: 52 years), 3.2%, 58.1%, 20.7%, and 18.0% presented with asymptomatic, mild, moderate, and severe COVID-19, respectively. Although 59.9% had no fatty liver on plain CT, mild, moderate, and severe fatty liver occurred in 13.1%, 18.9%, and 8.1%, respectively. Age and presence of fatty liver were significantly associated with severe COVID-19. CONCLUSION Our study showed that fatty liver on plain CT scan on admission can become a risk factor for severe COVID-19. This finding may help clinicians to easily triage COVID-19 patients.
Collapse
Affiliation(s)
- Ayako Okuhama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masatoshi Hotta
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
| | - Akira Kawashima
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yusuke Miyazato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mari Terada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - Gen Yamada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Makoto Inada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Lubna Sato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mitsuhiro Sato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yutaro Akiyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tetsuya Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takato Nakamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hidetoshi Nomoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Ide
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Keiji Nakamura
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Noriko Kinoshita
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kei Yamamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinichiro Morioka
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mugen Ujiie
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kayoko Hayakawa
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Kustuna
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yoshitaka Shida
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tsuyoshi Tajima
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Katsuji Teruya
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yumi Funato
- Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan
| | - Makiko Yamamoto
- Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinyu Izumi
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masayuki Hojo
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | | | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
6
|
Ide S, Hayakawa K, Yamamoto K, Tsuzuki S, Tanuma J, Ohara K, Yamada G, Okuhama A, Kanda K, Suzuki T, Akiyama Y, Miyazato Y, Nakamura K, Nomoto H, Nakamoto T, Ujiie M, Saito S, Morioka S, Ishikane M, Kinoshita N, Kutsuna S, Tanaka K, Ohmagari N. Positive ratio of polymerase chain reaction (PCR) and validity of pre-screening criteria at an outpatient screening center during the early phase of the COVID-19 epidemic in Japan. Jpn J Infect Dis 2021; 74:481-486. [PMID: 33642432 DOI: 10.7883/yoken.jjid.2020.813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Despite the increase in COVID-19 cases worldwide, the number of cases in Japan has been relatively low, and an explosive surge in the prevalence has not occurred. Since March 2020, the Ministry of Health, Labour and Welfare (MHLW) in Japan recommended original criteria for considering polymerase chain reaction (PCR) testing, although there was a lack of clear evidence for appropriate targets for COVID-19 testing. This study aimed to evaluate COVID-19 positive ratio and pre-screening criteria in Tokyo immediately after insurance-covered SARS-CoV-2 polymerase chain reaction testing became available in Japan. We tested 277 individuals (positive: 9.0%) from March 9-29, 2020. In total, 277 patients with mild symptoms in metropolitan Tokyo underwent SARS-CoV-2 PCR testing. The results revealed that 25 (9.0%) patients were PCR positive. The sensitivity and specificity of the MHLW criteria were 100% and 10.7%, respectively. When the criteria excluded nonspecific symptoms, fatigue, and dyspnea, sensitivity slightly decreased to 92%, and specificity increased to 22.2%. Specificity was highest when the fever criterion was ≥37.5°C for ≥4 days, and exposure/travel history, including age and underlying comorbidities, was considered. Our findings suggest that MHLW criteria, including symptoms and exposure/travel history, could support COVID-19 pre-screening.
Collapse
Affiliation(s)
- Satoshi Ide
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.,Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Kayoko Hayakawa
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Kei Yamamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Shinya Tsuzuki
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan.,Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
| | - Junko Tanuma
- AIDS Clinical Center, National Center for Global Health and Medicine, Japan
| | - Kaori Ohara
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Japan
| | - Gen Yamada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Ayako Okuhama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Tetsuya Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.,Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Yutaro Akiyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Yusuke Miyazato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Keiji Nakamura
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Hidetoshi Nomoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.,Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Takato Nakamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Mugen Ujiie
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.,Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Shinichiro Morioka
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.,Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Noriko Kinoshita
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.,Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Satoshi Kutsuna
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Keiko Tanaka
- Department of Nursing, National Center for Global Health and Medicine, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| |
Collapse
|
7
|
Kutsuna S, Asai Y, Matsunaga A, Kinoshita N, Terada M, Miyazato Y, Nakamoto T, Suzuki T, Saito S, Endo M, Kanda K, Kenji M, Takasaki J, Hojo M, Ishizaka Y, Ohmagari N. Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. J Infect Chemother 2021; 27:808-813. [PMID: 33531292 PMCID: PMC7836855 DOI: 10.1016/j.jiac.2021.01.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 12/01/2020] [Accepted: 01/12/2021] [Indexed: 02/07/2023]
Abstract
Introduction Among patients with coronavirus disease 2019 (COVID-19), the factors that affect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production remain unclear. This study aimed to identify such factors among patients convalescing from COVID-19. Methods This study comprised patients who had been diagnosed with COVID-19 between January 1 and June 30, 2020 and gave consent for anti-SARS-CoV-2 spike protein antibody measurement using enzyme-linked immunosorbent assay during their acute and/or convalescent phases. Factors related to elevated antibody titers and the relationship between the days from disease onset and the development of antibody titers were assessed. Results A total of 84 participants enrolled in the study. Nineteen participants had antibody titers measured during the convalescent phase only, and 65 participants had antibody titers measured during the acute and convalescent phases. The antibody titers peaked in weeks 5 and 6. The stepwise multivariate log-normal analysis revealed that male sex (P = 0.04), diabetes mellitus (P = 0.03), and high C-reactive protein levels during the disease course (P < 0.001) were associated with elevated IgG antibodies. Glucocorticoid use was not associated with antibody titers. Conclusion The study found that high values of maximum CRP levels during the acute phase, male sex, and diabetes mellitus were associated with elevated antibody titers. Antibody titers tended to be highest in the first 5 or 6 weeks after the onset of symptoms.
Collapse
Affiliation(s)
- Satoshi Kutsuna
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
| | - Yusuke Asai
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Akihiro Matsunaga
- Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - Noriko Kinoshita
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mari Terada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yusuke Miyazato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takato Nakamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tetsuya Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
| | - Mio Endo
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Maeda Kenji
- Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan
| | - Jin Takasaki
- Department of Respiratory Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masayuki Hojo
- Department of Respiratory Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yukihito Ishizaka
- Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan; Vice Director-General, National Center for Global Health and Medicine Research Institute, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
8
|
Akiyama Y, Morioka S, Wakimoto Y, Kawashima A, Kanda K, Okuhama A, Suzuki T, Miyazato Y, Nomoto H, Ide S, Nakamoto T, Nakamura K, Ota M, Moriyama Y, Takaya S, Yamada K, Taguchi M, Sugito E, Izuka S, Ishiguro K, Kobayashi T, Miyake W, Kubota S, Ishikane M, Kinoshita N, Yamamoto K, Ujiie M, Kutsuna S, Hayakawa K, Saito S, Ohmagari N. Non-COVID-19 Patients with Life-threatening Diseases Who Visited a Fever Clinic: A Single-center, Observational Study in Tokyo, Japan. Intern Med 2020; 59:3131-3133. [PMID: 33132334 PMCID: PMC7807116 DOI: 10.2169/internalmedicine.5614-20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Objective In fever clinics screening coronavirus disease (COVID-19), there could be patients with life-threatening diseases that physicians should not overlook. We exploratorily investigated the final diagnosis among non-COVID-19 hospitalized patients who visited the fever clinic. Methods This was a retrospective, observational, and single-centered study conducted in the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. We conducted a retrospective chart review of patients who visited the fever clinic in the NCGM from 11 March 2020 to 24 April 2020. Patients Patients who met the following clinical criteria visited the fever clinic in the NCGM: (1) body temperature >37.5°C, (2) any symptoms consistent with COVID-19 or (3) referral from local healthcare facilities. In the fever clinic, all patients who met the above criteria had severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test with nasopharyngeal swab specimens. Patients with severe symptoms or an unstable condition were sent to an outpatient clinic for infectious diseases for further evaluation and treatment. Results Among 1,470 patients who visited the fever clinic, 84 patients were hospitalized, and 45 of them were diagnosed as having COVID-19. Among the remaining 39 non-COVID-19 patients, there were nine patients with life-threatening diseases. The life-threatening diseases included acute heart failure, septic shock, pneumocystis pneumonia, peritonsillar abscess, and necrotizing fasciitis. Conclusion Physicians should evaluate each patient carefully while considering other life-threatening conditions even in such a COVID-19 pandemic era.
Collapse
Affiliation(s)
- Yutaro Akiyama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Shinichiro Morioka
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Yuji Wakimoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Akira Kawashima
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Kohei Kanda
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Ayako Okuhama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Tetsuya Suzuki
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Yusuke Miyazato
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Hidetoshi Nomoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Satoshi Ide
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Takato Nakamoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Keiji Nakamura
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Masayuki Ota
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Yuki Moriyama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Saho Takaya
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Kota Yamada
- Department of Diabetes, Endocrinology, and Metabolism, National Center for Global Health and Medicine, Japan
| | - Maho Taguchi
- Department of Diabetes, Endocrinology, and Metabolism, National Center for Global Health and Medicine, Japan
| | - Erika Sugito
- Department of Diabetes, Endocrinology, and Metabolism, National Center for Global Health and Medicine, Japan
| | - Shinji Izuka
- Division of Rheumatic Diseases, National Center for Global Health and Medicine, Japan
| | - Kenji Ishiguro
- Division of Rheumatic Diseases, National Center for Global Health and Medicine, Japan
| | - Toshiaki Kobayashi
- Division of Rheumatic Diseases, National Center for Global Health and Medicine, Japan
| | - Wataru Miyake
- Department of Cardiology, National Center for Global Health and Medicine, Japan
| | - Shuji Kubota
- Department of Cardiology, National Center for Global Health and Medicine, Japan
| | - Masahiro Ishikane
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Noriko Kinoshita
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Kei Yamamoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Mugen Ujiie
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Satoshi Kutsuna
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Kayoko Hayakawa
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| | - Sho Saito
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
- Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Japan
| | - Norio Ohmagari
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
| |
Collapse
|
9
|
Hayama H, Ishikane M, Sato R, Kanda K, Kinoshita N, Izumi S, Ohmagari N, Hiroi Y. Association of plain computed tomography-determined pulmonary artery-to-aorta ratio with clinical severity of coronavirus disease 2019. Pulm Circ 2020; 10:2045894020969492. [PMID: 33282198 PMCID: PMC7686624 DOI: 10.1177/2045894020969492] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 10/07/2020] [Indexed: 11/23/2022] Open
Abstract
Coronavirus disease (COVID-19) is associated with pulmonary hypertension due to pulmonary
embolism, which affects subsequent outcomes. However, definitive diagnosis of pulmonary
hypertension is difficult because of the risk of spreading the infection. Here, we assess
the utility of plane computed tomography in noninvasively predicting the clinical severity
of COVID-19.
Collapse
Affiliation(s)
- Hiromasa Hayama
- Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Rubuna Sato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Noriko Kinoshita
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinyu Izumi
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yukio Hiroi
- Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan
| | | |
Collapse
|
10
|
Okuhama A, Ishikane M, Katagiri D, Kanda K, Nakamoto T, Kinoshita N, Nunose N, Fukaya T, Kondo I, Katano H, Suzuki T, Ohmagari N, Hinoshita F. Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan. Emerg Infect Dis 2020; 26:2758-2761. [PMID: 32730734 PMCID: PMC7588553 DOI: 10.3201/eid2611.201956] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We report detection of severe acute respiratory syndrome coronavirus 2 RNA in hemodialysis effluent from a patient in Japan with coronavirus disease and prolonged inflammation. Healthcare workers should observe strict standard and contact precautions and use appropriate personal protective equipment when handling hemodialysis circuitry from patients with diagnosed coronavirus disease.
Collapse
|
11
|
Nakamura K, Morioka S, Kutsuna S, Iida S, Suzuki T, Kinoshita N, Suzuki T, Sugiki Y, Okuhama A, Kanda K, Wakimoto Y, Ujiie M, Yamamoto K, Ishikane M, Moriyama Y, Ota M, Nakamoto T, Ide S, Nomoto H, Akiyama Y, Miyazato Y, Hayakawa K, Saito S, Ohmagari N. Environmental surface and air contamination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient rooms by disease severity. Infect Prev Pract 2020; 2:100098. [PMID: 34316568 PMCID: PMC7550981 DOI: 10.1016/j.infpip.2020.100098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 10/07/2020] [Indexed: 01/22/2023] Open
Abstract
Background The coronavirus disease 2019 (COVID-19) continues to spread around the world. In addition to community-acquired infections, nosocomial infections are also a major social concern. The likelihood of environmental contamination and transmission of the virus based on disease severity is unknown. Methods We collected nasopharyngeal, environmental and air samples from patients with COVID-19 admitted to the National Centre for Global Health and Medicine between January 29th and February 29th, 2020. The patients were classified by severity of disease. The collected samples were tested using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time reverse transcription polymerase chain reaction (real-time RT-PCR). Results SARS-CoV-2 was not detected in a subset of 11 air samples. Of the 141 environmental samples collected from three patient bays and two single rooms, four samples tested positive for SARS-CoV-2 by real-time RT-PCR. Detections were made on the surface of a stethoscope used in the care of a patient with severe disease, on the intubation tube of a patient classified as critical (and on ventilator management), and on the surface of a gown worn by the nurse providing care. Conclusions Regardless of the patients' disease severity, SARS-CoV-2 was detected on very few environmental surfaces. However, detection of SARS-CoV-2 on stethoscopes used in the care of multiple patients and on the surface of gowns worn by clinical staff indicates that medical devices may be linked to the spread of infection.
Collapse
Affiliation(s)
- Keiji Nakamura
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinichiro Morioka
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Kutsuna
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shun Iida
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.,Division of Infectious Diseases Pathology, Department of Global Infectious Diseases, Tohoku University Graduate School of Medicine, Miyagi, Japan
| | - Tadaki Suzuki
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan
| | - Noriko Kinoshita
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tetsuya Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuko Sugiki
- Infection Control Team, National Center for Global Health and Medicine, Tokyo, Japan.,Department of Nursing, National Center for Global Health and Medicine, Tokyo, Japan
| | - Ayako Okuhama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kohei Kanda
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuji Wakimoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mugen Ujiie
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kei Yamamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuki Moriyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masayuki Ota
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takato Nakamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Ide
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hidetoshi Nomoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yutaro Akiyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yusuke Miyazato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kayoko Hayakawa
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
12
|
Hayakawa K, Kutsuna S, Kawamata T, Sugiki Y, Nonaka C, Tanaka K, Shoji M, Nagai M, Tezuka S, Shinya K, Saito H, Harada T, Moriya N, Tsuboi M, Norizuki M, Sugiura Y, Osanai Y, Sugiyama M, Okuhama A, Kanda K, Wakimoto Y, Ujiie M, Morioka S, Yamamoto K, Kinoshita N, Ishikane M, Saito S, Moriyama Y, Ota M, Nakamura K, Nakamoto T, Ide S, Nomoto H, Akiyama Y, Suzuki T, Miyazato Y, Gu Y, Matsunaga N, Tsuzuki S, Fujitomo Y, Kusama Y, Shichino H, Kaneshige M, Yamanaka J, Saito M, Hojo M, Hashimoto M, Izumi S, Takasaki J, Suzuki M, Sakamoto K, Hiroi Y, Emoto S, Tokuhara M, Kobayashi T, Tomiyama K, Nakamura F, Ohmagari N, Sugiyama H. SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine. Glob Health Med 2020; 2:107-111. [PMID: 33330786 DOI: 10.35772/ghm.2020.01036] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 04/22/2020] [Accepted: 04/25/2020] [Indexed: 11/08/2022]
Abstract
Due to the significant spread of a new type of coronavirus (SARS-CoV-2) infection (COVID-19) in China, the Chinese government blockaded several cities in Hubei Province. Japanese citizens lost a means of transportation to return back to Japan. The National Center for Global Health and Medicine (NCGM) helped the operation of charter flights for evacuation of Japanese residents from Hubei Province, and this article outlines our experiences. A total of five charter flights were dispatched, and the majority of returnees (793/829 [95.7%]) were handled at NCGM. A large number of personnel from various departments participated in this operation; 107 physicians, 115 nurses, 110 clerical staff, and 45 laboratory technicians in total. Several medical translators were also involved. In this operation, we conducted airborne precautions in addition to contact precautions. Eye shields were also used. The doctors collecting the pharyngeal swab used a coverall to minimize the risk of body surface contamination from secretions and droplets. Enhanced hand hygiene using alcohol hand sanitizer was performed. Forty-eight persons were ultimately hospitalized after the triage at NCGM operation, which was more than the number of persons triaged at the airport (n = 34). Of those hospitalized after NCGM triage, 8.3% (4/48 patients) ultimately tested positive for SARS-CoV-2, significantly higher than the positive rate among subjects not triaged (4/48 [8.3%] vs. 9/745 [1.2%]: p = 0.0057). NCGM participated in a large-scale operation to evacuate Japanese nationals from the COVID-19 epidemic area. We were able to establish a scheme through this experience that can be used in the future.
Collapse
Affiliation(s)
- Kayoko Hayakawa
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Kutsuna
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takeo Kawamata
- National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuko Sugiki
- Infection Control Team, National Center for Global Health and Medicine, Tokyo, Japan.,Department of Nursing, National Center for Global Health and Medicine, Tokyo, Japan
| | - Chiharu Nonaka
- Department of Nursing, National Center for Global Health and Medicine, Tokyo, Japan
| | - Keiko Tanaka
- Department of Nursing, National Center for Global Health and Medicine, Tokyo, Japan
| | - Michi Shoji
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masaki Nagai
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shunsuke Tezuka
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kazuyuki Shinya
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hiroki Saito
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takahiro Harada
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Nin Moriya
- Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Motoyuki Tsuboi
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masataro Norizuki
- Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yasuo Sugiura
- International Health Care Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yasuyo Osanai
- Department of Nursing, National Center for Global Health and Medicine, Tokyo, Japan.,International Health Care Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masaya Sugiyama
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Tokyo, Japan
| | - Ayako Okuhama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kohei Kanda
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuji Wakimoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Mugen Ujiie
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinichiro Morioka
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kei Yamamoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Noriko Kinoshita
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masahiro Ishikane
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Sho Saito
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuki Moriyama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masayuki Ota
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Keiji Nakamura
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Takato Nakamoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Ide
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hidetoshi Nomoto
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yutaro Akiyama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Tetsuya Suzuki
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yusuke Miyazato
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yoshiaki Gu
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Nobuaki Matsunaga
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinya Tsuzuki
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yumiko Fujitomo
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yoshiki Kusama
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hiroyuki Shichino
- Department of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masao Kaneshige
- Department of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan
| | - Junko Yamanaka
- Department of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan
| | - Miki Saito
- Department of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masayuki Hojo
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Masao Hashimoto
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinyu Izumi
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Jin Takasaki
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Manabu Suzuki
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Keita Sakamoto
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - Yukio Hiroi
- Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Sakurako Emoto
- Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Makoto Tokuhara
- Department of Palliative care, National Center for Global Health and Medicine, Tokyo, Japan
| | - Toshiaki Kobayashi
- Department of Rheumatology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Koichiro Tomiyama
- Department of Emergency Medicine & Critical Care, National Center for Global Health and Medicine, Tokyo, Japan
| | - Fumihiko Nakamura
- Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Norio Ohmagari
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Haruhito Sugiyama
- Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.,Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
13
|
Numata S, Keiichi I, Yamazaki S, Kanda K, Yaku H. P1826Computational fluid dynamic analysis of acute aortic dissection. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Mechanism of acute aortic dissection still is not well understood. It is very difficult to predict where, when, and how acute aortic dissection occurs. This time we focused on blood flow velocity (FV), wall shear stress (WSS), and oscillatory shear index (OSI) which is three dimensional fluctuations of WSS inside ascending aorta. It is well recognized that a higher or lower WSS may cause intimal dysfunction, which could result in the progression of atherosclerosis. Furthermore, because of the non-slip boundary mechanical equilibrium of forces, WSS will separate the inner and outer layers of the aorta. This sheer force could stress the medial tissue and result in degeneration. OSI has been reported as important hemodynamic parameter that is highly associated with the progression of atherosclerosis by inducing radical oxygen production of the endothelial cells. Therefore, OSI may be more closely associated with the degeneration of the media in comparison with WSS. This time FV, WSS, and OSI was evaluated using computational fluid dynamics to identify the location of acute aortic dissection entry.
Method
Using computed tomography data of three patients (Case A, B, C) who had acute aortic dissection, each three pre-dissection aorta model was made. Computer simulation images of four dimensional pulsatile blood flow was made and pulsatile cardiac flow from one cardiac cycle was simulated. A three-dimensional movie was made to evaluate FV, WSS, and OSI. One normal size aorta was evaluated as a control.
Results
In control, blood flow inside ascending aorta was laminar, on the contrary, spiral flow was observed in three dissection cases. FV was slightly higher in dissection case (control: 0.56m/s, A: 0.77m/s, B: 1.05m/s, C: 0.35m/s). Maximum WSS in ascending aorta was 3.24Pa in control. In dissection cases, there was patchy high (A: 18.6Pa, B: 25.6Pa, C: 4.0Pa,) WSS lesion in ascending aorta. In case A and B, these patchy high lesions are close to the entry site. In all three dissection case, OSI was high around entry site.
Figure 1
Conclusion
According to our computer simulation, patchy high WSS and high OSI lesion is related with acute dissection entry site at the ascending aorta.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- S Numata
- Kyoto Prefectural University of Medicine, Cardiovascular surgery, Kyoto, Japan
| | - I Keiichi
- Kyoto Prefectural University of Medicine, Cardiovascular surgery, Kyoto, Japan
| | - S Yamazaki
- Kyoto Prefectural University of Medicine, Cardiovascular surgery, Kyoto, Japan
| | - K Kanda
- Kyoto Prefectural University of Medicine, Cardiovascular surgery, Kyoto, Japan
| | - H Yaku
- Kyoto Prefectural University of Medicine, Cardiovascular surgery, Kyoto, Japan
| |
Collapse
|
14
|
Kanda K, Fujimoto K, Mochizuki R, Ishida K, Lee B. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer. BMC Cancer 2019; 19:904. [PMID: 31506070 PMCID: PMC6734590 DOI: 10.1186/s12885-019-6113-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Accepted: 08/30/2019] [Indexed: 12/13/2022] Open
Abstract
Background Appropriate assessment is essential for the management of chemotherapy-induced peripheral neuropathy (CIPN), an intractable symptom that cannot yet be palliated, which is high on the list of causes of distress for cancer patients. However, objective assessment by medical staff makes it easy to underestimate the symptoms and effects of CIPN in cancer survivors. As a result, divergence from subjective evaluation of cancer survivors is a significant problem. Therefore, there is an urgent need to develop a subjective scale with high accuracy and applicability that reflects the experiences of cancer patients. We developed a comprehensive assessment scale for CIPN in cancer survivors, named the Comprehensive Assessment Scale for Chemotherapy-Induced Peripheral Neuropathy in Survivors of Cancer (CAS-CIPN), and demonstrated its reliability and validity. Methods We developed a questionnaire based on qualitative studies of peripheral neuropathy in Japanese cancer patients and literature review. Twelve cancer experts confirmed the content validity of the questionnaire. A draft version comprising 40 items was finalized by a pilot test on 100 subjects. The participants in the present study were 327 Japanese cancer survivors. Construct validity was determined by factor analysis, and internal validity by confirmation factor analysis and Cronbach’s α. Results Factor analysis showed that the structure consisted of 15 items in four dimensions: “Threatened interference in daily life by negative feelings”, “Impaired hand fine motor skills”, “Confidence in choice of treatment/management,” and “Dysesthesia of the palms and soles.” The CAS-CIPN internal consistency reliability was 0.826, and the reliability coefficient calculated using the Spearman-Brown formula [q = 2r/(1 + r)] was 0.713, confirming high internal consistency and stability. Scores on this scale were strongly correlated with Gynecologic Oncology Group-Neurotoxicity scores (r = 0.714, p < 0.01), confirming its criterion-related validity. Conclusions The CAS-CIPN is an assessment tool with high reliability and validity for the comprehensive evaluation of CIPN in cancer survivors. The CAS-CIPN is simple to use, and can be used by medical professionals for appropriate situational assessment and intervention.
Collapse
Affiliation(s)
- K Kanda
- Department of Nursing, Takasaki University of Health and Welfare, 501 Nakaoruimachi, Takasakishi, Gunma, 370-0033, Japan.
| | - K Fujimoto
- Department of Nursing, Takasaki University of Health and Welfare, 501 Nakaoruimachi, Takasakishi, Gunma, 370-0033, Japan
| | - R Mochizuki
- The Jikei University School of Medicine, School of Nursing, 8-3-1, Kokuryocho, Chofu, Tokyo, 182-8570, Japan
| | - K Ishida
- Niigata College of Nursing, 240 Shinnancho, Joetsu, Nigata, 943-0147, Japan
| | - B Lee
- Department of Occupation, Gunma University Graduate School of Health Sciences, 3-39-22, Showamachi, Maebashi, Gunma, 371-8514, Japan
| |
Collapse
|
15
|
Sugiyama K, Kanda K, Iwasaki S, Nakazawa M, Hashikura H, Iguchi T, Sekimoto H, Itoh S, Sumita K, Takahashi A, Yamamoto J. Integral Experiments in a 120-cm Lithium Sphere. ACTA ACUST UNITED AC 2017. [DOI: 10.13182/fst85-a39977] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Sugiyama
- Tohoku University Department of Nuclear Engineering Aramaki-Aoba, Sendai 980, Japan (0222) 22-1800
| | - K. Kanda
- Tohoku University Department of Nuclear Engineering Aramaki-Aoba, Sendai 980, Japan (0222) 22-1800
| | - S. Iwasaki
- Tohoku University Department of Nuclear Engineering Aramaki-Aoba, Sendai 980, Japan (0222) 22-1800
| | - M. Nakazawa
- University of Tokyo Nuclear Engineering Research Laboratory Tokai-mura, Ibaraki-ken, 319-11, Japan (0292) 82-1611
| | - H. Hashikura
- University of Tokyo Nuclear Engineering Research Laboratory Tokai-mura, Ibaraki-ken, 319-11, Japan (0292) 82-1611
| | - T. Iguchi
- University of Tokyo Department of Nuclear Engineering Hongo, Bunkyo-ku, Tokyo 113, Japan (03) 812-2111
| | - H. Sekimoto
- Tokyo Institute of Technology Research Laboratory of Nuclear Reactors O-okayama, Meguro-ku, Tokyo 152, Japan (03) 726-1111
| | - S. Itoh
- Nagoya University Department of Nuclear EngineeringFuro-cho, Chikusa-ku, Nagoya 464, Japan (052) 781-5111
| | - K. Sumita
- Osaka University Department of Nuclear EngineeringYamadaoka, Suita, Osaka 565, Japan (06) 877-5111
| | - A. Takahashi
- Osaka University Department of Nuclear EngineeringYamadaoka, Suita, Osaka 565, Japan (06) 877-5111
| | - J. Yamamoto
- Osaka University Department of Nuclear EngineeringYamadaoka, Suita, Osaka 565, Japan (06) 877-5111
| |
Collapse
|
16
|
Abstract
Our purpose was to evaluate whether or not and when phenotypic modulation of smooth muscle cells (SMCs) in hybrid vascular prostheses preincorporated with SMCs occurs upon implantation. Two types of hybrid vascular grafts incorporated with vascular cells derived from canine jugular veins were prepared: grafts containing a collagen gel layer covered with an endothelial monolayer at the luminal surface (Model I graft) and those containing an endothelial monolayer and SMC multilayer (Model II graft). They were bilaterally implanted into carotid arteries of the same dogs from which the cells had been harvested for 2 wk (n = 3) and 12 wk (n = 3). The time-dependent changes in populations of three SMC phenotypes (synthetic, intermediate, and contractile) in the neoarterial layers were quantified by morphometric evaluation using a transmission electron microscope in hybrid vascular grafts. Before implantation, all the SMCs were of the synthetic phenotype. In Model II grafts at 2 wk, synthetic and intermediate SMCs were dominant especially in the luminal layer. On the other hand, neoarterial layers at 12 wk were dominated by contractile SMCs, which were evenly distributed throughout the entire neoarterial tissues. A markedly delayed phenotypic reversion was noted for the Model I grafts at 12 wk. In the hybrid grafts, during about 3 mo of implantation, neoarterial SMCs transformed from the synthetic to the contractile phenotypes, which was promoted by SMC incorporation.
Collapse
MESH Headings
- Animals
- Arteries/physiology
- Arteries/ultrastructure
- Blood Vessel Prosthesis
- Cell Transplantation
- Cells, Cultured/cytology
- Cells, Cultured/physiology
- Cells, Cultured/ultrastructure
- Dogs
- Endothelium, Vascular/cytology
- Endothelium, Vascular/physiology
- Jugular Veins/cytology
- Microscopy, Electron
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/physiology
- Phenotype
- Regeneration/physiology
Collapse
Affiliation(s)
- K Kanda
- Department of Bioengineering, National Cardiovascular Center Research Institute, Osaka, Japan
| | | | | |
Collapse
|
17
|
Kanda K, Sato H, Miyakoshi T, Kitano T, Kanebako H, Adachi K. Friction control of mechanical seals in a ventricular assist device. Biosurface and Biotribology 2015. [DOI: 10.1016/j.bsbt.2015.06.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
18
|
Bertozzi AI, Munzer C, Fouyssac F, Andre N, Boetto S, Leblond P, Bourdeaut F, Dufour C, Deshpande RK, Bhat KG, Mahalingam S, Muscat A, Cain J, Ferguson M, Popovski D, Algar E, Rossello FJ, Jayasekara S, Watkins DN, Hodge J, Ashley D, Hishii M, Saito M, Arai H, Han ZY, Richer W, Lucchesi C, Freneaux P, Nicolas A, Grison C, Pierron G, Delattre O, Bourdeaut F, Epari S, TS N, Gupta T, Chinnaswamy G, Sastri JG, Shetty P, Moiyadi A, Jalali R, Fay-McClymont T, Johnston D, Janzen L, Guger S, Scheinemann K, Fleming A, Fryer C, Hukin J, Mabbott D, Huang A, Bouffet E, Lafay-Cousin L, Kawamura A, Yamamoto K, Nagashima T, Bartelheim K, Benesch M, Buchner J, Gerss J, Hasselblatt M, Kortmann RD, Fleischack G, Quiroga E, Reinhard H, Schneppenheim R, Seeringer A, Siebert R, Timmermann B, Warmuth-Metz M, Schmid I, Fruhwald MC, Fruhwald MC, Bartelheim K, Seeringer A, Kerl K, Kortmann RD, Warmuth-Metz M, Hasselblatt M, Schneppenheim R, Siebert R, Klingebiel T, Al-Kofide A, Khafaga Y, Al-Hindi H, Dababo M, Ul-Haq A, Anas M, Barria MG, Siddiqui K, Hassounah M, Ayas M, Al-Shail E, Hasselblatt M, Jeibmann A, Eikmeier K, Linge A, Johann P, Koos B, Bartelheim K, Kool M, Pfister SM, Fruhwald MC, Paulus W, Hasselblatt M, Schuller U, Junckerstorff R, Rosenblum MK, Alassiri AH, Rossi S, Bartelheim K, Schmid I, Gottardo N, Toledano H, Viscardi E, Witkowski L, Nagel I, Oyen F, Foulkes WD, Paulus W, Siebert R, Schneppenheim R, Fruhwald MC, Schrey D, Malietzis G, Chi S, Dufour C, Lafay-Cousin L, Marshall L, Carceller F, Moreno L, Zacharoulis S, Bhardwaj R, Chakravadhanula M, Ozals V, Hampton C, Metpally R, Grillner P, Asmundsson J, Gustavsson B, Holm S, Johann PD, Korshunov A, Ryzhova M, Kerl K, Milde T, Witt O, Jones DTW, Hovestadt V, Gajjar A, Hasselblatt M, Fruhwald M, Pfister S, Kool M, Finetti M, Pons ADC, Selby M, Smith A, Crosier S, Wood J, Skalkoyannis B, Bailey S, Clifford S, Williamson D, Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Rutkowski S, Timmermann B, Kortmann RD, Schneppenheim R, Warmuth-Metz M, Gerss J, Siebert R, Graf N, Boos J, Nysom K, Fruhwald MC, Kerl K, Moreno N, Holsten T, Ahlfeld J, Mertins J, Hotfilder M, Kool M, Bartelheim K, Schleicher S, Handgretinger R, Fruhwald M, Meisterernst M, Kerl K, Schmidt C, Ahlfeld J, Moreno N, Dittmar S, Pfister S, Fruhwald M, Kool M, Meisterernst M, Schuller U, Chan GCF, Shing MMK, Yuen HL, Li RCH, Ling SL, Slavc I, Peyrl A, Chocholous M, Azizi A, Czech T, Dieckmann K, Haberler C, Leiss U, Gotti G, Biassoni V, Schiavello E, Spreafico F, Pecori E, Gandola L, Massimino M, Mertins J, Kornelius K, Moreno N, Holsten T, Fruhwald M, Kool M, Meisterernst M, Yano H, Nakayama N, Ohe N, Ozeki M, Kanda K, Kimura T, Hori T, Fukao T, Iwama T, Weil AG, Diaz A, Gernsback J, Bhatia S, Ragheb J, Niazi T, Khatib Z, Kerl K, Holsten T, Moreno N, Zoghbi A, Meisterernst AM, Birks D, Griesinger A, Amani V, Donson A, Posner R, Dunham C, Kleinschmidt-DeMasters BK, Handler M, Vibhakar R, Foreman N, Bhardwaj R, Ozals V, Hampton C, Zhou L, Catchpoole D, Chakravadhanula M, Kakkar A, Biswas A, Suri V, Sharma M, Kale S, Mahapatra A, Sarkar C, Torchia J, Picard D, Ho KC, Khuong-Quang DA, Louterneau L, Bourgey M, Chan T, Golbourn B, Cousin LL, Taylor MD, Dirks P, Rutka JT, Bouffet E, Hawkins C, Majewski J, Kim SK, Jabado N, Huang A, Chang JHC, Confer M, Chang A, Goldman S, Dunn M, Hartsell W. ATYPICAL TERATOID RHABDOID TUMOUR. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Yasuda Y, Kanda K, Nishioka S, Tanimoto Y, Kato C, Saito A, Fukuchi S, Nakanishi Y, Tochikubo K. Regulation of L-alanine-initiated germination ofBacillus subtilis spores by alanine racemase. Amino Acids 2013; 4:89-99. [PMID: 24190560 DOI: 10.1007/bf00805804] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/1991] [Accepted: 05/25/1992] [Indexed: 11/30/2022]
Abstract
Germination ofBacillus subtilis spores was initiated by L-Ala and competitively inhibited by D-Ala, suggesting the presence of an alanine receptor. The spores showed alanine racemase activity in the spore coat. To investigate the role of alanine racemase (L → D) on germination, net racemase activity was determined using diphenylamine as a germination inhibitor and germination was measured using D-penicillamine as a racemase inhibitor. Apparent affinity of L-Ala to the germinant receptor was more than 1000 times higher than that to the racemase. Germination increased in the presence of D-penicillamine, when the concentration of L-Ala was low and that of spores was high. Racemase activity was optimal at 65°C at pH 9.0 and germination at 43°C at pH 7.2. Under unfavorable growth conditions such as high population of spores in limited nutrients, high temperature and high pH, spore alanine racemase converted the germinant actively to the inhibitor and this conversion may regulate germination for survival of the population.
Collapse
Affiliation(s)
- Y Yasuda
- Department of Microbiology, Nagoya City University Medical School, 467, Mizuho-Ku, Nagoya, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Kanda K, Watanabe T, Yamanami M, Sakai O, Yaku H, Nakayama Y. 150 * IN VIVO TISSUE-ENGINEERED SMALL DIAMETER "BIOTUBE". Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt372.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Gamage CD, Koizumi N, Perera AKC, Muto M, Nwafor-Okoli C, Ranasinghe S, Kularatne SAM, Rajapakse RPVJ, Kanda K, Lee RB, Obayashi Y, Ohnishi M, Tamashiro H. Carrier Status of Leptospirosis Among Cattle in Sri Lanka: A Zoonotic Threat to Public Health. Transbound Emerg Dis 2012; 61:91-6. [DOI: 10.1111/tbed.12014] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2012] [Indexed: 11/29/2022]
Affiliation(s)
- C. D. Gamage
- Department of Global Health and Epidemiology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - N. Koizumi
- Department of Bacteriology; National Institute of Infectious Diseases; Tokyo Japan
| | - A. K. C. Perera
- Municipal Veterinary Department; Colombo Municipal Council; Colombo Sri Lanka
| | - M. Muto
- Department of Bacteriology; National Institute of Infectious Diseases; Tokyo Japan
| | - C. Nwafor-Okoli
- Department of Global Health and Epidemiology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - S. Ranasinghe
- Department of Pathobiology; Faculty of Veterinary Medicine and Animal Science; University of Peradeniya; Peradeniya Sri Lanka
| | - S. A. M. Kularatne
- Department of Medicine; Faculty of Medicine; University of Peradeniya; Peradeniya Sri Lanka
| | - R. P. V. J. Rajapakse
- Department of Pathobiology; Faculty of Veterinary Medicine and Animal Science; University of Peradeniya; Peradeniya Sri Lanka
| | - K. Kanda
- Department of Global Health and Epidemiology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - R. B. Lee
- Behavioral Sciences Department; De La Salle University; Manila Philippines
| | - Y. Obayashi
- Department of Global Health and Epidemiology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - M. Ohnishi
- Department of Bacteriology; National Institute of Infectious Diseases; Tokyo Japan
| | - H. Tamashiro
- Department of Global Health and Epidemiology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| |
Collapse
|
22
|
Yamanaka S, Kanda K, Saito T, Umena Y, Kawakami K, Shen JR, Kamiya N, Okumura M, Nakamura H, Yamaguchi K. Electronic and Spin Structures of the CaMn4O5(H2O)4 Cluster in OEC of PSII Refined to 1.9Å X-ray Resolution. Advances in Quantum Chemistry Volume 64 2012. [DOI: 10.1016/b978-0-12-396498-4.00016-8] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
23
|
Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E, Chiba T. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 2011; 31:3111-23. [PMID: 22056877 PMCID: PMC3290745 DOI: 10.1038/onc.2011.498] [Citation(s) in RCA: 148] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Chitinase 3-like 1 (CHI3L1), one of mammalian members of the chitinase family, is expressed in several types of human cancer, and elevated serum level of CHI3L1 is suggested to be a biomarker of poor prognosis in advanced cancer patients. However, the overall biological function of CHI3L1 in human cancers still remains unknown. Studies were performed to characterize the role of CHI3L1 in cancer pathophysiology utilizing human colorectal cancer samples and human cell lines. Plasma protein and tissue mRNA expression levels of CHI3L1 in colorectal cancer were strongly upregulated. Immunohistochemical analysis showed that CHI3L1 was expressed in cancer cells and CHI3L1 expression had a significant association with the number of infiltrated macrophages and microvessel density. By utilizing trans-well migration and tube formation assays, overexpression of CHI3L1 in SW480 cells (human colon cancer cells) enhanced the migration of THP-1 cells (human macrophage cells) and HUVECs (human endothelial cells), and the tube formation of HUVECs. The knockdown of CHI3L1 by RNA interference or the neutralization of CHI3L1 by anti-CHI3L1 antibody displayed strong suppression of CHI3L1-induced migration and tube formation. Cell proliferation assay showed that CHI3L1 overexpression significantly enhanced the proliferation of SW480 cells. ELISA analysis showed that CHI3L1 increased the secretion of inflammatory chemokines, IL-8 and MCP-1, from SW480 cells through mitogen-activated protein kinase (MAPK) signaling pathway. Both neutralization of IL-8 or MCP-1 and inhibition or knockdown of MAPK in SW480 cells significantly inhibited CHI3L1-induced migration and tube formation. In a xenograft mouse model, overexpression of CHI3L1 in HCT116 cells (human colon cancer cells) enhanced the tumor growth as well as macrophage infiltration and microvessel density. In conclusion, CHI3L1 expressed in colon cancer cells promotes cancer cell proliferation, macrophage recruitment and angiogenesis. Thus, the inhibition of CHI3L1 activity may be a novel therapeutic strategy for human colorectal cancer.
Collapse
Affiliation(s)
- M Kawada
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Yamanaka S, Isobe H, Kanda K, Saito T, Umena Y, Kawakami K, Shen JR, Kamiya N, Okumura M, Nakamura H, Yamaguchi K. Possible mechanisms for the O–O bond formation in oxygen evolution reaction at the CaMn4O5(H2O)4 cluster of PSII refined to 1.9Å X-ray resolution. Chem Phys Lett 2011. [DOI: 10.1016/j.cplett.2011.06.021] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
25
|
Tanaka S, Kondo H, Kanda K, Ashino T, Nakamachi T, Sekikawa K, Iwakura Y, Shioda S, Numazawa S, Yoshida T. Involvement of interleukin-1 in lipopolysaccaride-induced microglial activation and learning and memory deficits. J Neurosci Res 2011; 89:506-14. [PMID: 21290410 DOI: 10.1002/jnr.22582] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2010] [Revised: 09/16/2010] [Accepted: 11/11/2010] [Indexed: 11/11/2022]
Abstract
We have developed an animal model of learning and memory impairment associated with activation of microglia in the mouse brain. Injection of lipopolysaccharide into the CA1 region of the mouse hippocampus resulted in an increased production of inflammatory cytokines, such as interleukin-1β. Immunostaining for interleukin-1β revealed an increase in the signal at 6 hr after lipopolysaccharide injection. Immunopositive cells for interleukin-1β were colocalized with those immunopositive for CD11b. When subacute lipopolysaccharide treatment (20 μg/2 μl/injection, bilaterally for 5 consecutive days) was performed, long-term activation of microglia and learning and memory deficits as evaluated using a step-through passive avoidance test were observed in the wild-type mice. Gene expression of the N-methyl-D-aspartate receptor NR1 and NR2A subunits was also decreased by the lipopolysaccharide treatment. In contrast, activation of microglia and the associated behavioral deficits were not observed in mice lacking interleukin-1α and -1β following the subacute lipopolysaccharide treatment, together with little change in the gene expression of NR1 and NR2A subunits. However, the subacute lipopolysaccharide treatment produced almost similar changes in those parameters in the tumor necrosis factor-α knockout mice as in the wild-type animals. The injection of interleukin-1β neutralizing antibody with lipopolysaccharide for 5 consecutive days resulted in the improvement of lipopolysaccharide-induced learning and memory deficits. These findings suggest that the expression of interleukin-1 plays an important role in lipopolysaccharide-induced activation of microglia and the associated functional deficits in learning and memory.
Collapse
Affiliation(s)
- S Tanaka
- Department of Biochemical Toxicology, School of Pharmacy, Showa University, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Nakanishi Y, Kanda K, Akitake R, Seno H, Chiba T, Ono K, Kayahara T, Yamashita Y. Metastatic gastrointestinal stromal tumors mimicking gastrointestinal polyposis. Endoscopy 2010; 42 Suppl 2:E37-8. [PMID: 20073011 DOI: 10.1055/s-0029-1215263] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- Y Nakanishi
- Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto University Graduate School of Medicine, Kyoto, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Omoto S, Okada M, Kang Y, Kanda K, Haruyama Y, Tono S, Matsui S. Comparison of EB Exposure Characteristics between HSQ and Calix Arene of High Resolution Negative Resist. J PHOTOPOLYM SCI TEC 2010. [DOI: 10.2494/photopolymer.23.97] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
|
30
|
Yoshikawa S, Muramoto K, Nakagawa N, Taniguchi M, Kanda K, Shinzawa-Itoh K, Maeda T, Yamashita E, Tsukihara T. X-ray structure of carbon monoxide at copper site of the dinuclear site of cytochrome coxidase. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308090788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
31
|
Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K, Sekine T, Igarashi T, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M. Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness. J Med Genet 2008; 45:182-6. [PMID: 18310267 DOI: 10.1136/jmg.2007.052944] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis. BS with sensorineural deafness (SND, OMIM602522) is a newly identified phenotype caused by mutations in the BSND gene that encodes barttin, a beta-subunit for chloride channel ClC-Ka and ClC-Kb and classified as type IV BS. Type IV BS features the most severe phenotype entailing life-threatening neonatal volume depletion and chronic renal failure developing during infancy. A recent report described a case of BS with SND from a consanguineous family who showed homozygous mutations in the CLCNKA and CLCNKB genes. This case indicated the possibility of the occurrence of digenic inheritance in BS with SND resulting from double mutations in the CLCNKA and CLCNKB genes. SUBJECT AND RESULTS The current report concerns a 2-year-old girl from a non-consanguineous family with BS accompanied by SND. In our case, four loss-of-function mutations, consisting of mutations in both parental alleles in both CLCNKA and CLCNKB, were identified. The paternal allele had a nonsense mutation (Q260X) in CLCNKA and a splicing site mutation (IVS17+1 g>a) in CLCNKB. The maternal allele had a large deletion mutation (about 12 kbp) extending from CLCNKA to CLCNKB. Our case provides clear evidence that loss-of-function alleles in both alleles of both CLCNKA and CLCNKB results in a phenotype indistinguishable from that of mutations in BSND (type IV BS). CONCLUSIONS Recent advances in genetics have resulted in a better understanding of many human inherited diseases, but most of them are monogenic disorders and more complex inheritance patterns remain unresolved. Our case provides clear evidence of digenic inheritance outside the scope of Mendelian inheritance disorders.
Collapse
Affiliation(s)
- K Nozu
- Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Futakuchi H, Ueda M, Kanda K, Fujino K, Yamaguchi H, Noda S. Transcriptional expression of survivin and its splice variants in cervical carcinomas. Int J Gynecol Cancer 2007; 17:1092-8. [PMID: 17877643 DOI: 10.1111/j.1525-1438.2007.00833.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The objective of this study was to evaluate transcriptional expression of survivin and the two splice variants (survivin-2B and survivin-ΔEx3) in cervical carcinomas. The gene expression levels of survivin and its splice variants in 11 human cervical carcinoma cell lines and 20 malignant and 12 normal cervical tissue samples were analyzed using quantitative reverse transcription–polymerase chain reaction analysis. Gene expression levels of survivin and survivin-ΔEx3 in cell lines were higher than those in normal cervical tissues (P= 0.0193 and 0.0489). Transcript levels of survivin and survivin-ΔEx3 in carcinoma tissues were also higher than those in normal controls (P= 0.0016 and 0.0011). Gene expression levels of survivin and survivin-ΔEx3 in adenocarcinomas were statistically higher than those in squamous cell carcinomas (P= 0.0260 and 0.0487). There was no significant difference in survivin-2B gene expression between malignant and normal cervical samples or different histologic types. The ratios of survivin-2B/survivin and survivin-ΔEx3/survivin in carcinoma tissues were higher than those in normal controls (P= 0.0288 and 0.0081). Interestingly, the ratio of survivin-2B/survivin was increased in the patients with higher stages and with pelvic lymph node metastasis (P= 0.0205 and 0.0437), respectively. We conclude that survivin and its splice variants might be involved in the pathogenesis and development of cervical carcinomas.
Collapse
Affiliation(s)
- H Futakuchi
- Department of Obstetrics and Gynecology, Osaka Medical College, Osaka, Japan
| | | | | | | | | | | |
Collapse
|
33
|
Abstract
The expression of c-myc is deregulated in Burkitt's lymphoma by the translocation t(8;14). Most of the increased c-myc expression is from the P1 promoter, which is normally a minor promoter. How the P1 promoter is activated by the immunoglobulin heavy chain gene enhancers is not understood. We identified a YY1 site in the immunoglobulin heavy-chain gene HS3 enhancer, which increased c-myc P1 promoter activity, and a MARE site, which decreased c-myc P1 activity. Small Maf proteins bound to the MARE site both in vitro and in vivo, recruited histone deacetylase 2, and resulted in deacetylation of histones H3 and H4 at the c-myc promoter region. In contrast, YY1 recruited CBP and increased histone acetylation at the c-myc promoter. Rb interacts with YY1 to prevent DNA binding in normal B cells, but no significant interaction with YY1 was detected in Burkitt's cells, and binding of YY1 to the HS3 enhancer was observed by chromatin immunoprecipitaton. Increased expression of MafK and/or decreased expression of YY1 by silencing RNA downregulated endogenous c-myc mRNA levels and increased the sensitivity of the cells to doxorubicin. Mutation of the major active sites (nuclear factor-kappa B and YY1) in the enhancers prevented c-myc activation.
Collapse
Affiliation(s)
- H-M Hu
- Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Stanford, CA, USA
| | | | | | | |
Collapse
|
34
|
Affiliation(s)
- K Kume
- Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu, Japan
| | | | | | | | | |
Collapse
|
35
|
Yamagami T, Kanda K, Kato T, Hirota T, Nishida K, Yoshimatsu R, Matsumoto T, Nishimura T. Embolisation of proximal anastomotic pseudoaneurysm developing after surgical repair of abdominal aortic aneurysm with a bifurcated graft with n-butyl cyanoacrylate. Br J Radiol 2006; 79:e193-5. [PMID: 17213297 DOI: 10.1259/bjr/97367208] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
We report a 60-year-old man who after undergoing surgical repair of an abdominal aortic aneurysm with a bifurcated graft subsequently developed a proximal anastomotic pseudoaneurysm, which was successfully treated by embolisation with n-butyl cyanoacrylate.
Collapse
Affiliation(s)
- T Yamagami
- Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-chyo, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M. Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006; 16 Suppl 1:179-82. [PMID: 16515587 DOI: 10.1111/j.1525-1438.2006.00505.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Single-nucleotide polymorphism at -670 of Fas gene promoter (A/G) was examined in a total of 354 blood samples from normal healthy women and gynecological cancer patients. They consisted of 95 normal, 83 cervical, 108 endometrial, and 68 ovarian cancer cases. Eighty-three patients with cervical cancer had statistically higher frequency of GG genotype and G allele than 95 controls (P= 0.0353 and 0.0278, respectively). There was no significant difference in the genotype or allele prevalence between control subjects and endometrial or ovarian cancer patients. The Fas -670 GG genotype was associated with an increased risk for the development of cervical cancer (OR = 2.56, 95% CI = 1.08-6.10) compared with the AA genotype. The G allele also increased the risk of cervical cancer (OR = 1.60, 95% CI = 1.05-2.43) compared with the A allele. Germ-line polymorphism of Fas gene promoter -670 may be associated with the risk of cervical cancer in a Japanese population.
Collapse
Affiliation(s)
- M Ueda
- Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki Osaka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Short AEZ, Kanda K. The water scavenger beetles of Mongolia with new records from the Selenge River Basin (Coleoptera: Hydrophilidae). Proceedings of the Academy of Natural Sciences of Philadelphia 2006. [DOI: 10.1635/i0097-3157-155-1-9.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
38
|
Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M. Fas gene promoter –670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006. [DOI: 10.1136/ijgc-00009577-200602001-00028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Single-nucleotide polymorphism at −670 of Fas gene promoter (A/G) was examined in a total of 354 blood samples from normal healthy women and gynecological cancer patients. They consisted of 95 normal, 83 cervical, 108 endometrial, and 68 ovarian cancer cases. Eighty-three patients with cervical cancer had statistically higher frequency of GG genotype and G allele than 95 controls (P= 0.0353 and 0.0278, respectively). There was no significant difference in the genotype or allele prevalence between control subjects and endometrial or ovarian cancer patients. The Fas −670 GG genotype was associated with an increased risk for the development of cervical cancer (OR = 2.56, 95% CI = 1.08–6.10) compared with the AA genotype. The G allele also increased the risk of cervical cancer (OR = 1.60, 95% CI = 1.05–2.43) compared with the A allele. Germ-line polymorphism of Fas gene promoter −670 may be associated with the risk of cervical cancer in a Japanese population.
Collapse
|
39
|
Affiliation(s)
- M Yamasaki
- Third Department of Internal Medicine, University of Occupational and Enviromental Health, School of Medicine, Kitakyusyu, Japan
| | | | | | | | | |
Collapse
|
40
|
Affiliation(s)
- K Kume
- Third Dept. of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
| | | | | | | | | |
Collapse
|
41
|
Hotta H, Kanai C, Uchida S, Kanda K. Stimulation of the nucleus basalis of Meynert increases diameter of the parenchymal blood vessels in the rat cerebral cortex. Neurosci Lett 2004; 358:103-6. [PMID: 15026159 DOI: 10.1016/j.neulet.2004.01.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2003] [Revised: 12/29/2003] [Accepted: 01/02/2004] [Indexed: 11/18/2022]
Abstract
To verify the hypothesis that stimulation of the nucleus basalis of Meynert (NBM) induces vasodilation in the cerebral cortical parenchyma, we investigated whether the diameter of parenchymal blood vessels of rat parietal cortex is increased during stimulation of NBM using histological techniques. The parietal cortex was fixed by immersion fixation in situ during focal electrical stimulation of the NBM, which increased cortical blood flow. Cortical tissues were sectioned horizontally to the cortical surface, and the parenchymal blood vessels were morphometrically analyzed using electron microscopy. Mean inner diameter of the parenchymal blood vessels in NBM stimulated rats (5.51+/-0.33 microm) was significantly larger than that in non-stimulated control rats (4.93+/-0.23 microm). The result suggests that functional vasodilation in the cortical parenchyma during NBM stimulation correlates with histologically observed vasodilation in the cortical parenchyma.
Collapse
Affiliation(s)
- H Hotta
- Motor and Autonomic Nervous System Integration Research Group, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan.
| | | | | | | |
Collapse
|
42
|
Ito T, Ohmori S, Kanda K, Kawano S, Murata Y, Seo H. Changes in serum 1,25-dihydroxyvitamin D3 and mRNAs for osteocalcin and alkaline phosphatase in femur unloaded by tail suspension in rats. Environ Med 2003; 38:103-6. [PMID: 12703522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
To elucidate the mechanism involved in the development of disuse atrophy of bone by skeletal unloading, changes in osteocalcin and alkaline phosphatase mRNAs, markers for bone formation, were studied in the hind limb bones of tail-suspended rats. Tail suspension for 8 and 14 days resulted in a significant decrease in osteocalcin mRNA in the femur when compared with age-matched non-suspended controls. Serum 1,25-dihydroxyvitamin D3 decreased to 60% of the control level after 8 days of skeletal unloading but regained almost normal levels over the next 7 days. Since it is known that vitamin D3 up regulates and glucocorticoid down regulates transcription of the osteocalcin gene, the endocrine response evoked by tail suspension may have aggravated the disuse atrophy caused by skeletal unloading in this study.
Collapse
Affiliation(s)
- T Ito
- Department of Endocrinology and Metabolism, Division of Molecular and Cellular Adaptation, Research Institute of Environmental Medicine, Nagoya University, Nagoya
| | | | | | | | | | | |
Collapse
|
43
|
Kawano S, Ohmori S, Kanda K, Ito T, Murata Y, Seo H. Adrenocortical response to tail-suspension in young and old rats. Environ Med 2003; 38:7-12. [PMID: 12703518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
We recently showed that increased glucocorticoid secretion aggravates disuse atrophy when induced by skeletal unloading. Disuse atrophy in the elderly is becoming a serious problem in many developed countries. In this study we attempted to examine how aging affects the glucocorticoid response to skeletal unloading. Three groups of rats (aged 5 weeks, 12 months and 18 months) were subjected to 7 days of hind limb unloading by tail-suspension. Urinary excretion of corticosterone over a 24-hr period were monitored every other day. Corticosterone excretion in the control group of 5-week-old rats was initially 87.4 +/- 12.8 ng/day and did not change throughout the experiment. Tail-suspension experiments yielded a significant increase (more than 3 fold) in excretion on days 1 and 3 of the suspension before returning to control levels. In the 12-month-old rats, a marked increase in the basal corticosterone level was observed in the control rats throughout the experiment, while the increase by tail-suspension was attenuated with a transient, significant increase on day 5. In 18-month-old rats, a further increase in the basal level was observed in the control group, although excretions tended to increase steadily from day 1 to day 3 and remained high until day 7. Urinary excretion of corticosterone among the 18-month-old suspension group was similar to those observed in the control group. These results indicate that the younger (5-week-old) rats adapted the stress load caused either by tail-suspension or manipulation alone faster than the older rats did (12 or 18 months old). The observation that basal corticosterone excretion increases with age suggests, alterations in the hypothalamic-pituitary-adrenal axis among the aged rats which might aggravates disuse atrophy induced by skeletal unloading.
Collapse
Affiliation(s)
- S Kawano
- Department of Endocrinology and Metabolism, Division of Molecular and Cellular Adaptation, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
| | | | | | | | | | | |
Collapse
|
44
|
Kanda K, Satoh S, Okano T, Shimada Y, Yaku H, Kitamura N. Ascending aortic cannulation via left thoracotomy for distal aortic arch aneurysm operation. J Cardiovasc Surg (Torino) 2002; 43:853-5. [PMID: 12483179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
We have cannulated the ascending aorta for cardiopulmonary bypass via left thoracotomy in order to avoid conventional retrograde perfusion from the femoral arteries, which is associated with an increased risk of cerebral embolism. We use silk sutures to retract the anterior margin of the opened pericardium from the chest wall, which provides good exposure and easy control of the ascending aorta. Between July 1997 and November 2000, cannulation proved easy to do and reliable in 24 serial patients.
Collapse
Affiliation(s)
- K Kanda
- Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
| | | | | | | | | | | |
Collapse
|
45
|
Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda K, Hung YC, Ueki M. Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol 2002; 16:391-402. [PMID: 12587534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/28/2023] Open
Abstract
Various types of cell adhesion molecules and matrix metalloproteinases (MMPs) seem to play an important role in the invasion process of endometriosis; however, limited investigation has focused on their gene expression in human peritoneal endometriotic lesions. A total of 63 endometriotic tissues were surgically obtained from 35 women with endometriosis, which included 43 pigmented and 20 non-pigmented lesions. Gene expression levels of E-cadherin, alpha- and beta-catenin, MMP-2, MMP-9 and membrane-type 1 (MT1)-MMP in these endometriotic lesions were compared with those in normal eutopic endometrium obtained from 12 women without endometriosis. MMP-2, MMP-9 and MT1-MMP mRNA expression in pigmented lesions was significantly higher than that in normal endometrium (p < 0.05), whereas E-cadherin, alpha- and beta-catenin mRNA expression was not suppressed in endometriotic lesions. There was a close correlation between MMP-2 or MT1-MMP and E-cadherin, alpha- or beta-catenin gene expression in 63 endometriotic tissues examined (p < 0.01). Immunohistochemical expression of E-cadherin, alpha- and beta-catenin in glandular epithelial cells was positive not only for all of seven cases with normal eutopic endometrium but also for 9 of 11 with ovarian endometriosis. MMP expression in ectopic endometrium was much greater than that in eutopic endometrium. These results suggest that endometriotic tissues expressing MMPs might be invasive and simultaneously possess cell-to-cell adhesion property in pelvic peritoneal foci.
Collapse
Affiliation(s)
- M Ueda
- Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kanda K, Nakatsuji H, Yonezawa T. Theoretical study of the metal chemical shift in nuclear magnetic resonance spectroscopy. Manganese complexes. J Am Chem Soc 2002. [DOI: 10.1021/ja00332a023] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Murakami Y, Kanda K, Yokota K, Kanayama H, Kagawa S. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol Urol 2002; 5:113-9. [PMID: 11690558 DOI: 10.1089/10915360152559594] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Our purpose was to elucidate the clinical roles of the "immuno-proteosome," which is involved in the accelerated pathway of the major histocompatibility complex (MHC) class I-restricted antigen presentation system, in renal cell carcinoma (RCC). The relative expression of six proteosome subunits (existing subunits X, Y, and Z and immunoproteosome subunits LMP7, LMP2, and MECL1) in 54 RCCs was investigated using RT-PCR analysis and was compared with clinicopathological measures, including patient outcome. Expression of the LMP7 and LMP2 genes was significantly low in high-grade tumors, and that of the LMP7 and MECL1 genes was significantly low in high-stage tumors. Low levels of LMP7, LMP2, and MECL1 expression were strongly associated with shortened survival (LMP7: P = 0.0002, LMP2: P < 0.0001, MECL1: P < 0.0047). The levels of subunits X, Y, and Z had no significant correlation with those measures. These findings suggest that RCCs with low level of immuno-proteosome subunit expression have a disorder in their antigen-presentation system. As a consequence, they may escape from immune surveillance and worsen patient outcome.
Collapse
Affiliation(s)
- Y Murakami
- Department of Urology, School of Medicine, The University of Tokushima, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
48
|
Kanda K, Ohderaotoshi T, Shimojyo A, Kato F, Murata A. An extrachromosomal prophage naturally associated with
Bacillus thuringiensis
serovar
israelensis. Lett Appl Microbiol 2002. [DOI: 10.1046/j.1365-2672.1999.00535.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- K. Kanda
- Institute of Applied Microbiology, Department of Applied Biological Sciences, Faculty of Agriculture, Saga University, Saga, Japan
| | - T. Ohderaotoshi
- Institute of Applied Microbiology, Department of Applied Biological Sciences, Faculty of Agriculture, Saga University, Saga, Japan
| | - A. Shimojyo
- Institute of Applied Microbiology, Department of Applied Biological Sciences, Faculty of Agriculture, Saga University, Saga, Japan
| | - F. Kato
- Institute of Applied Microbiology, Department of Applied Biological Sciences, Faculty of Agriculture, Saga University, Saga, Japan
| | - A. Murata
- Institute of Applied Microbiology, Department of Applied Biological Sciences, Faculty of Agriculture, Saga University, Saga, Japan
| |
Collapse
|
49
|
Nakano K, Okada Y, Tanizawa T, Kanda K, Morita E, Tsukada J, Tanaka Y. [Not Available]. CLINICAL CALCIUM 2001; 11:1658-1663. [PMID: 15775482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
|
50
|
Ohmori S, Kanda K, Kawano S, Kambe F, Seo H. Effects of estrogen on tail suspension-induced disuse atrophy in ovariectomized rats: evaluation of the expression of interleukin-6 mRNA in the femur. Environ Med 2001; 45:12-4. [PMID: 12353531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
It is known that estrogen deficiency results in osteoporosis in human and experimental animals. However, how this deficiency affects the development of disuse bone atrophy is not well understood. Recently, it has been reported that estrogen affects the production of cytokines such as interleukin 6 (IL-6) which acts as local bone-resorbing factor. We thus studied how estrogen deficiency caused by ovariectomy and estrogen supplements affects the expression of IL-6 mRNA in the femur of tail-suspended rats. Five-week old female Wistar rats were ovariectomized and divided into two groups. One group received an intramuscular injection of estradiol dipropionate once a week (OVX-E2 group), and the other received the vehicle alone (OVX group). After the third injection, the rats were subjected to tail suspension in metabolic cages for 1, 3, 5 and 7 days. The wet weight of femurs significantly decreased after day 3 of tail-suspension in the OVX group. However, no significant decrease was observed in the OVX-E2 group. The expression of IL-6 mRNA estimated by RT-PCR (reverse transcription coupled polymerase chain reaction) in the femur significantly increased on day 5 after tail suspension in the OVX group. In the OVX-E2 group, that level significantly decreased on day 1 after the commencement of tail suspension. During suspension the level tended to be lower than that in the OVX group, a significant difference being observed on days 5 and 7 of suspension. The present results suggest that estrogen administration to OVX rats prevents both IL-6 production in the femur and the development of disuse bone atrophy induced by tail suspension.
Collapse
Affiliation(s)
- S Ohmori
- Department of Endocrinology and Metabolism, Division of Molecular and Cellular Adaptation, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
| | | | | | | | | |
Collapse
|